Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Prediction for the development of new distant metastases using serum microRNAs in patients with metastatic breast cancer treated with eribulin

ABSTRACT: The combination of serum miRNAs could be a classifier for predicting the development of new distant metastasis in breast cancer patients during the treatment of eribulin

ORGANISM(S): Homo sapiens

PROVIDER: GSE110651 | GEO | 2019/02/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Prediction for the development of new distant metastases using serum microRNAs in patients with metastatic breast cancer treated with eribulin

Project description:Prediction for the development of new distant metastases using serum microRNAs in patients with metastatic breast cancer treated with eribulin

| PRJNA434193 | ENA

Breast cancer cell lines treated with eribulin and paclitaxel

Project description:Eribulin mesylate is a synthetic macrocyclic ketone analog of the marine sponge natural product halichondrin B. Eribulin is a mechanistically unique inhibitor of microtubule dynamics, leading to inhibition of microtubule growth in the absence of effects on microtubule shortening at microtubule plus ends, and formation of nonproductive tubulin aggregates. In this study, we investigated whether selective signal pathways were associated with eribulin activity compared to paclitaxel, which stabilizes microtubules, based on gene expression profiling of cell line panels of breast, endometrial, and ovarian cancer in vitro. 27 breast cancer cell lines treated with eribulin and paclitaxel for 24 hours at concentration 10xIC50. Three technical replicates were included. for eribulin , paclitaxel and untreated cell lines.

2014-10-02 | E-GEOD-50811 | biostudies-arrayexpress

Endometrial cancer cell lines treated with eribulin and paclitaxel

Project description:Eribulin mesylate is a synthetic macrocyclic ketone analog of the marine sponge natural product halichondrin B. Eribulin is a mechanistically unique inhibitor of microtubule dynamics, leading to inhibition of microtubule growth in the absence of effects on microtubule shortening at microtubule plus ends, and formation of nonproductive tubulin aggregates. In this study, we investigated whether selective signal pathways were associated with eribulin activity compared to paclitaxel, which stabilizes microtubules, based on gene expression profiling of cell line panels of breast, endometrial, and ovarian cancer in vitro. 19 endometrial cancer cell lines treated with eribulin and paclitaxel for 24 hours at concentration 10xIC50. Three technical replicates were included. for eribulin , paclitaxel and untreated cell lines.

2014-10-02 | E-GEOD-50830 | biostudies-arrayexpress

Ovarian cancer cell lines treated with eribulin and paclitaxel

Project description:Eribulin mesylate is a synthetic macrocyclic ketone analog of the marine sponge natural product halichondrin B. Eribulin is a mechanistically unique inhibitor of microtubule dynamics, leading to inhibition of microtubule growth in the absence of effects on microtubule shortening at microtubule plus ends, and formation of nonproductive tubulin aggregates. In this study, we investigated whether selective signal pathways were associated with eribulin activity compared to paclitaxel, which stabilizes microtubules, based on gene expression profiling of cell line panels of breast, endometrial, and ovarian cancer in vitro. 21 ovarian cancer cell lines treated with eribulin and paclitaxel for 24 hours at concentration 10xIC50. Three technical replicates were included for eribulin , paclitaxel and untreated cell lines.

2014-10-02 | E-GEOD-50831 | biostudies-arrayexpress

Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: an NRG Oncology / Gynecologic Oncology Group Study

Project description:Accurate methods to predict nodal and distant metastasis are needed in endometrioid endometrial cancer (EEC) patients to advance personalized care and reduce both overtreatment and undertreatment. A transcript-based classifier for predicting risk of nodal and distant metastasis in EEC patients was developed, and shown to outperform a panel of clinical and molecular features We used microarrays to detail the gene expression in EEC patients and identified a classifer to predict nodal and distant metastasis

2022-12-30 | GSE120490 | GEO

Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer.

Project description: Not available

| S-EPMC6726239 | biostudies-literature

Quantitative proteomic analysis identifies TUBB2A as a novel protein biomarker for prediction of distant metastatic breast cancer

Project description:Metastasis of breast cancer to other distant organs is fatal to patients. However, few studies have revealed biomarkers associated with distant metastatic breast cancer. Furthermore, the inability of current biomarkers such as HER2, ER and PR, in accurately differentiating between distant metastatic breast cancers from non-distant metastatic ones necessitates the development of novel biomarkers. An integrated proteomics approach that combines filter-aided sample preparation, tandem mass tag labeling (TMT), high pH fractionation, and high resolution MS was applied to acquire in-depth proteome data of distant metastatic breast cancer FFPE tissue. Bioinformatics analyses for gene ontology and signaling pathways using differentially expressed proteins (DEPs) were performed to investigate molecular characteristics of distant metastatic breast cancer. In addition, real-time polymerase chain reaction (RT-PCR) and invasion/migration assays were performed to validate the differential regulation and functional capability of biomarker candidates. A total of 9,459 and 8,760 proteins were identified from the pooled sample set and the individual sample set, respectively. Through our stringent criteria, TUBB2A was selected as a novel biomarker. The metastatic functions of the candidate were subsequently validated. Bioinformatics analysis using DEPs were able to characterize the overall molecular features of distant metastasis as well as investigate the differences across breast cancer subtypes. Our study is the first to explore the distant metastatic breast cancer proteome using FFPE tissue. The depth of our dataset enabled the discovery of novel biomarker and the investigation of proteomic characteristics of distant metastatic breast cancer. The distinct molecular features of breast cancer subtypes were also observed. Our proteomic data has important utility as a valuable resource for the research on distant metastatic breast cancer.

2020-06-05 | PXD016061 | Pride

Ovarian cancer cell lines treated with eribulin and paclitaxel

2014-10-02 | GSE50831 | GEO

Endometrial cancer cell lines treated with eribulin and paclitaxel

2014-10-02 | GSE50830 | GEO

Breast cancer cell lines treated with eribulin and paclitaxel

2014-10-02 | GSE50811 | GEO